» Articles » PMID: 17558858

Analysis of APC/beta-catenin Genes Mutations and Wnt Signalling Pathway in Desmoid-type Fibromatosis

Overview
Journal Pathology
Specialty Pathology
Date 2007 Jun 15
PMID 17558858
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The abnormalities of the Wnt signalling pathway in desmoid-type fibromatosis were analysed, with the purpose of exploring the mechanism of tumorigenesis and progression.

Methods: The clinical and histopathological features of 96 cases were analysed. Beta-catenin, cyclin-D1, c-myc, and Ki-67 proteins were detected in 69 cases using formalin-fixed, paraffin-embedded tissues. Using the same materials, apoptosis of the tumour cells was investigated by terminal deoxynucleotidyl transferase mediated dUTP nick end-labelling (TUNEL) testing. Polymerase chain reaction (PCR), denaturing high performance liquid chromatography (DHPLC) assay, and sequencing were performed to detect abnormalities of the adenomatous polyposis coli (APC) and beta-catenin genes.

Results: APC gene mutations were found in 18 cases (26.1%, 18/69). Somatic mutations of codon 41 in exon 3 of beta-catenin were detected in 13 cases (18.8%, 13/69). No correlation of beta-catenin abnormal expression with the mutations of APC gene or beta-catenin gene was identified (p>0.05). The cases with abnormal beta-catenin expression showed a higher level of c-myc protein expression (69.7%, 23/33) than those without (22.2%, 8/36, p = 0.001). The apoptotic indices (AIs) were significantly lower in cyclin-D1 positive cases and c-myc positive cases (p = 0.015, p = 0.007).

Conclusions: There are somatic mutations of the APC and beta-catenin gene in desmoid-type fibromatosis, and there are abnormalities in the Wnt signalling pathway. These abnormalities may result in aberrant cell proliferation and apoptosis, which are likely to be important factors in tumorigenesis and progression.

Citing Articles

Precision oncology: The role of minimally-invasive ablation therapy in the management of solid organ tumors.

Fazlollahi F, Makary M World J Radiol. 2025; 17(1):98618.

PMID: 39876886 PMC: 11755905. DOI: 10.4329/wjr.v17.i1.98618.


Novel insights into biomarkers of progression in Desmoid tumor.

Liu B, Sun Z, Zhou R, Shen D, Zhu S, Chen L Front Oncol. 2023; 13:1206800.

PMID: 37601698 PMC: 10434506. DOI: 10.3389/fonc.2023.1206800.


Intraabdominal sporadic desmoid tumors and inflammation: an updated literature review and presentation and insights on pathogenesis of synchronous sporadic mesenteric desmoid tumors occurring after surgery for necrotizing pancreatitis.

Prete F, Rotelli M, Stella A, Calculli G, Sgaramella L, Amati A Clin Exp Med. 2022; 23(3):607-617.

PMID: 35913675 PMC: 10284958. DOI: 10.1007/s10238-022-00849-6.


Molecular testing of soft tissue tumors.

Rottmann D, Abdulfatah E, Pantanowitz L Diagn Cytopathol. 2022; 51(1):12-25.

PMID: 35808975 PMC: 10084007. DOI: 10.1002/dc.25013.


Molecular Pathogenesis of Sporadic Desmoid Tumours and Its Implications for Novel Therapies: A Systematised Narrative Review.

McLean T, Duchi S, Di Bella C Target Oncol. 2022; 17(3):223-252.

PMID: 35446005 PMC: 9217905. DOI: 10.1007/s11523-022-00876-z.